Literature DB >> 24289491

MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.

Robert W Georgantas1, Katie Streicher, Xiaobing Luo, Lydia Greenlees, Wei Zhu, Zheng Liu, Philip Brohawn, Christopher Morehouse, Brandon W Higgs, Laura Richman, Bahija Jallal, Yihong Yao, Koustubh Ranade.   

Abstract

Expression profiling of microRNAs in melanoma lesional skin biopsies compared with normal donor skin biopsies, as well as melanoma cell lines compared with normal melanocytes, revealed that hsa-miR-206 was down-regulated in melanoma (-75.4-fold, P = 1.7 × 10(-4)). MiR-206 has been implicated in a large number of cancers, including breast, lung, colorectal, ovarian, and prostate cancers; however, its role in tumor development remains largely unknown, its biologic function is poorly characterized, and its targets affecting cancer cells are largely unknown. MiR-206 reduced growth and migration/invasion of multiple melanoma cell lines. Bioinformatics identified cell cycle genes CDK2, CDK4, Cyclin C, and Cyclin D1 as strong candidate targets. Western blots and 3'UTR reporter gene assays revealed that miR-206 inhibited translation of CDK4, Cyclin D1, and Cyclin C. Additionally, hsa-miR-206 transfection induced G1 arrest in multiple melanoma cell lines. These observations support hsa-miR-206 as a tumor suppressor in melanoma and identify Cyclin C, Cyclin D1, and CDK4 as miR-206 targets.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  G1 arrest; cell cycle; cell growth; invasion; microRNA; migration

Mesh:

Substances:

Year:  2014        PMID: 24289491     DOI: 10.1111/pcmr.12200

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  25 in total

Review 1.  The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.

Authors:  Muhammad Nauman Aftab; Marcel E Dinger; Ranjan J Perera
Journal:  Arch Biochem Biophys       Date:  2014-07-24       Impact factor: 4.013

2.  Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma.

Authors:  Rong Tian; Tao Liu; Li Qiao; Mei Gao; Jing Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 3.  MicroRNA heterogeneity in melanoma progression.

Authors:  Anita Thyagarajan; Kenneth Y Tsai; Ravi P Sahu
Journal:  Semin Cancer Biol       Date:  2019-06-01       Impact factor: 15.707

4.  MicroRNA-206 inhibits the viability and migration of human lung adenocarcinoma cells partly by targeting MET.

Authors:  Xi Chen; Zhong-Kai Tong; Jian-Ya Zhou; Ya-Ke Yao; Shu-Meng Zhang; Jian-Ying Zhou
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

Review 5.  Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease.

Authors:  Keith Richard Mitchelson; Wen-Yan Qin
Journal:  World J Biol Chem       Date:  2015-08-26

6.  MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.

Authors:  Duo Li; Dong-Qiong Li; Dan Liu; Xiao-Jun Tang
Journal:  Cell Oncol (Dordr)       Date:  2016-01-07       Impact factor: 6.730

7.  MiR-203 promotes the growth and migration of ovarian cancer cells by enhancing glycolytic pathway.

Authors:  Zhao Xiaohong; Fan Lichun; Xie Na; Zou Kejian; Xiao Xiaolan; Wang Shaosheng
Journal:  Tumour Biol       Date:  2016-09-21

Review 8.  MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention.

Authors:  Anita Thyagarajan; Ahmed Shaban; Ravi Prakash Sahu
Journal:  J Pharmacol Exp Ther       Date:  2017-10-20       Impact factor: 4.030

9.  HDAC9 overexpression confers invasive and angiogenic potential to triple negative breast cancer cells via modulating microRNA-206.

Authors:  Eric Salgado; Xuehai Bian; Amber Feng; Hyunsuk Shim; Zhongxing Liang
Journal:  Biochem Biophys Res Commun       Date:  2018-06-23       Impact factor: 3.575

Review 10.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.